Waters European Oligonucleotides Forum 2023

WEOF is back for 2023, and this time we will do it 100% virtually to allow even more people to participate. But don't expect to see only some presentations! We have put together for you an interesting agenda with Live Demos, customer talks, and the chance to ask our experts your questions. It will be a great opportunity to learn more about the advancements in oligonucleotide analysis and about the analytical challenges and successes of your peers.

• Join our virtual Live Demos
• Hear from other scientists like you about their approaches and experiences
• Stay up to date with the latest analytical developments for nucleic acids

The agenda will be a mix of talks from the scientific community and Waters presentations. We will discuss current analytical needs and show some Live Demos of LC/MS solutions and software:

AGENDA

10:00 Welcome and Short Introduction

• Speaker: David Muñoz (Waters Corporation)

10:05 Waters Live Demo: Impurity Analysis by LC/MS

• Speaker: Emma L Harry (Waters Corporation)

10:25 Customer Talk: Cytiva Sweden AB

Analysis of Oligonucleotides using BioAccord LC-MS

• Speaker: Filip Bergqvist (Senior Scientist)

Topic: intact analysis of oligonucleotides, specifically development/performance with IP-RPC

10:40 Customer Talk: BioNTech Manufacturing GmbH

QC Analytics for mRNA therapies

• Speaker: Jonas Sander

Topic: How BioNTech has masterdto set up QC analytics for mRNQ therapies and the added value of Waters solutions

10:55 MaxPeak Premier Technology for Oligonucleotide Analysis

• Speaker: Ali Tiss (Waters Corporation)

11:10 Waters Live Demo: Software

CONFIRM & INTACT app

• Speaker: Chris Knowles (Waters Corporation)

11:30 Q&A with Waters

You ask - our application chemists answer

11:45 Closing

INVITED GUEST SPEAKER

Filip Bergqvist (Senior Scientist, Cytiva Sweden AB)

Filip is leading bioanalytical activities to support product development and application work for bioprocessing. His main expertise is LC-MS, where he is developing methods for characterization of proteins and nucleic acid therapeutics.

Dr. Jonas Sander (BioNTech Manufacturing GmbH)

(further info will follow soon)

YOUR WATERS HOSTS

David Muñoz (Principal Biopharma Market Development Manager, Waters Corporation)

David will be your host for this event. He completed his PhD in Biochemistry at Nottingham Trent University, focused on the effects of toxins on glioma cells. After this he joined Lonza to work as a research and development scientist using different analytical techniques to characterize antibodies and proteins. Later he worked for Thermo Fisher Scientific as applications specialist and Biopharma Expert, and as business development manager in two CDMOs, focusing on antibodies and viral vector projects. David joined Waters in June 2022 as principal biopharma market development manager.

Emma L Harry (European Applications Laboratory Team Manager, Waters Corporation)

Emma completed her PhD in Analytical Chemistry at Loughborough University, focused on the development of ion mobility mass spectrometry for complex mixtures.

After her post doctoral research at University of Leicester and having worked as analytical scientist at Hall Analytical, using a variety of analytical techniques, Emma joined Waters in June 2019 as a senior applications chemist in the Demo lab in Wilmslow. In 2021 she was promoted to European applications lab manager.

Chris Knowles (Senior Applications Scientist, Waters Corporation)

Chris is currently working as a Principal Domain Specialist (Applications science) at Waters, having been with the company for 5 years. He works with the Waters informatics teams to help deliver the waters_connect software applications. His focus has been on the CONFIRM Sequence application. His background is in Bioprocessing, having worked at FUJIFILM Diasynth Biotechnologies for 3 years as a principal scientist in Mammalian cell culture, following completion of a PhD in mammalian cell line engineering at the University of Aberdeen in 2016.

Ali Tiss (Sales Specialist Biopharma Chemistry, Europe South, Waters Corporation)

Ali completed his Ph.D. in biochemistry and structural biology at the Mediterranean University (CNRS, Marseille, France), where he contributed to the R&D of the anti-obesity drug, Xenical®, developed by Roche Ltd. Then, he spent about 20 years of academic research (France, UK, Kuwait) in biochemistry, liquid chromatography, mass-spectrometry, and proteomics, focusing on detecting and characterizing biomarkers related to human diseases (cancer, diabetes, obesity). Ali joined Waters in October 2021 as a BioPharma and New Modalities Specialist in Chemistry for Southern Europe.